ADC Therapeutics (ADCT) Q3 2024 earnings summary

Executive summary

• Achieved solid operational performance in Q3 2024, with ZYNLONTA as the flagship product driving growth in DLBCL and indolent lymphomas, and expanding into earlier lines and new indications.

• Product revenues increased 26.3% year-over-year to $18.0 million in Q3 2024, with net loss narrowing by 5.9% and commercial brand profitability achieved for ZYNLONTA.

• Advanced clinical pipeline with LOTIS-5 full enrollment expected by year-end 2024 and LOTIS-7 interim safety and efficacy data anticipated in December 2024.

• Discontinued ADCT-601 solid tumor program due to unfavorable benefit-risk profile, shifting focus to exatecan-based ADCs for solid tumors.

• Completed $97.4 million equity offering in May 2024, further strengthening liquidity and supporting ongoing R&D and commercialization efforts.

Financial highlights

• Q3 2024 net product revenues reached $18.0 million (up from $14.3 million in Q3 2023), with year-to-date ZYNLONTA revenues at $52.9 million, nearly flat year-over-year.

• Net loss for Q3 2024 was $44.0 million ($0.42/share), improved from $46.7 million ($0.57/share) in Q3 2023; adjusted net loss was $29.4 million ($0.28/share), down from $32.4 million ($0.39/share) year-over-year.

• Operating expenses for Q3 2024 were $54.0 million (up 6.7% YoY), with R&D at $32.5 million, S&M at $10.7 million, and G&A at $10.0 million.

• Cash and cash equivalents stood at $274.3 million as of September 30, 2024, expected to fund operations into mid-2026.

• Gross margin remains high due to low cost of product sales relative to revenue.

Outlook and guidance

• LOTIS-5 full enrollment expected by year-end 2024, with data readout anticipated by end of 2025.

• LOTIS-7 interim safety and efficacy data on 15-20 patients to be presented in December 2024, with further updates in H1 2025.

• Updated phase II IIT data in indolent lymphomas to be presented at ASH 2024; regulatory discussions planned based on data maturity.

• IND-enabling studies ongoing for exatecan-based ADCs, with one candidate moving toward IND in 2025.

• Cash runway projected into mid-2026, assuming receipt of anticipated regulatory milestone payments.